SuspendedPhase 3

Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.

Stopped: Indefinite hold by company

United States260 participantsStarted 2025-01

Plain-language summary

The purpose of this study is to investigate the efficacy of enzastaurin compared to placebo in preventing arterial events (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) leading to intervention or mortality attributable to an arterial event in patients with vEDS confirmed with pathogenic heterozygous COL3A1 gene mutations predicted to derive a mutant protein.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects aged 18 - 60 years old at time of initial screening.
✓. Adolescent subjects aged 12 - 17 years old, may be considered to enroll later in the clinical trial pending interim analysis.
✓. Diagnosis for VEDS (vascular Ehlers Danlos Syndrome), with a confirmed and documented COL3A1 genetic variant.
✓. Subject should be stable, having no VEDS-related vascular events within the past 3 months prior to enrollment.
✓. Confirmed use of contraception for both male and female participants.

Exclusion criteria

✕. Inability to swallow or receive intact tablets.
✕. Currently being treated with CYP3A4 inhibitors within 4 weeks prior to enrollment.
✕. Known allergy or hypersensitivity to enzastaurin.
✕. Patient currently pregnant or breast feeding.

What they're measuring

Time to intervention for an arterial event (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) or mortality attributable to an arterial event.

Timeframe: 30 months

Trial details

NCT IDNCT05463679

SponsorAytu BioPharma, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06

View on ClinicalTrials.gov More Vascular Ehlers-Danlos Syndrome trials